Objective:To investigate the effect of miRNA-5089-5p (miR-5089-5p) on proliferation and migration ability of esophageal cancer in vitro and its relationship with the expression of cathepsin B (CTSB) gene.Methods:Quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect the expression levels of miR-5089-5p in 31 tissue samples from patients who underwent esophageal cancer resection and the corresponding pericarcinomatous tissues between in March 2017 and in December 2019 at Huangshi Central Hospital of Edong Healthcare Group, and TE-13, EC9706, Eca109, KYSE30 cell lines and normal esophageal mucosal epithelial HET-1A cells. The esophageal cancer cells with the lowest expression level of miR-5089-5p were divided into 2 groups: miR-5089-5p group transfected with miR-5089-5p mimics and the negative control group with negative control sequence. qRT-PCR was used to detect the expression level of miR-5089-5p after transfection for 48 h. CCK-8 method and scratch healing test were used to detect the proliferation and migration ability of cells in the two groups. The online tools microRNA.org and Deepbase v2.0 were used to predict the target genes of miR-5089-5p. The dual luciferase reporter gene assay was used to verify the target gene of miR-5089-5p. qRT-PCR and Western blot were used to detect the expression level of target genes in the two groups. The expressions of cell proliferation-related protein (PCNA and Ki-67) and migration-related protein (N-Cadherin and Twist) were detected by using Western blot.Results:The relative expression level of miR-5089-5p in esophageal cancer and pericarcinomatous tissues was 1.54±0.53 and 7.07±1.25, respectively ( t = 24.06, P < 0.01). The relative expression level of miR-5089-5p in the esophageal cancer cell lines was lower than that of normal esophageal mucosal epithelial HET-1A cells (all P < 0.05), and the cell line with the lowest relative expression was Eca109 cells (0.12±0.03). Compared with the negative control group, the proliferation ability of Eca109 cells in miR-5089-5p group was gradually reduced with the transfection time extension, and the difference was statistically significant between the two groups since 48 h (all P < 0.05), and the migration ability was also reduced [scratch healing rate: (29±5)% vs.(64±8)%, t=3.91, P < 0.01]. The online tool predicted that the target gene of miR-5089-5p might be CTSB, and the dual luciferase reporter gene assay confirmed that miR-5089-5p complemented CTSB 3'UTR. qRT-PCR results showed that compared with the negative control group, the relative expression level of CTSB mRNA in Eca109 cells of miR-5089-5p group was reduced (0.23±0.04 vs.1.01±0.09, t = 8.27, P < 0.01). Western blot results showed that the expression level of CTSB protein was reduced, and the expression levels of cell proliferation-related protein PCNA, Ki-67 and cell migration-related protein N-Cadherin, Twist were also reduced. Conclusions:The expression level of miR-5089-5p in esophageal cancer tissues and cell lines is low. miR-5089-5p can inhibit proliferation and migration of esophageal cancer Eca109 cells. The mechanism may be achieved by down-regulating CTSB gene expression.

To evaluate the feasibility, safety and efficacy of percutaneous stent implantation for treating left main coronary artery (LMCA) stenosis. Methods Consecutive patients with unprotected left main coronary artery disease treated by stent-based percutaneous intervention (PCI) at 6 medical centers in China were enrolled. Procedural data and clinical outcomes were obtained from all patients. Results From January 2001 to December 2004, 138 patients (79 males and 59 females; mean age: 69.7±5.8 years)underwent PCI for LMCA stenosis. Bare metal stents (BMS) were implanted in 51 patients with non-bifurcational lesions and in 5 patients with bifurcational lesions from January of 2001 to June of 2003 (BMS group);. Drug eluting stents (DES) were used unselectively to cover both bifurcational and non-bifurcational lesions in 86 patients from July of 2003 to December of 2004 (DES group). Procedural success rate of the 138 cases was 98% (135/138). One patient (0.7%) with bifurcation lesion who was treated with DES died from severe heart failure 2 weeks after the procedure. During a mean follow up period of 21.3 ± 5.6 months, one patient died from renal failure, one from sudden cardiac death, 4 underwent target lesion revascularization (TLR) in the BMS group, which all occurred in patients with bifurcational lesions; whereas in the DES group no deaths occurred and only one patient with bifurcational lesion had TLR. Conclusions (1) PCI is feasible and relatively safe to treat unprotected left main coronary artery disease in elderly patients at medical centers with experienced professionals. (2) BMS and DES have similar immediate and long-term efficacy in the treatment of ostium and shaft lesions of the LMCA. (3) DES are strongly suggested in the therapy of distal bifurcation lesion of unprotected LMCA.

Objective:To observe the expression of long-chain noncoding RNA (lncRNA) SCAMP1-AS1 in esophageal cancer tissues, and explore the effect of SCAMP1-AS1 on the proliferation and migration of esophageal cancer cells and the possible molecular mechanism.Methods:Real-time fluorescent quantitative polymerase chain reaction (RT-qPCR) was used to detect the expression level of SCAMP1-AS1 in 37 cases of esophageal cancer tissues and adjacent tissues surgically resected in Huangshi Central Hospital of Edong Medical Group from March 2017 to August 2020. RT-qPCR was also used to detect the expression level of SCAMP1-AS1 in 4 types of esophageal cancer cells (EC9706, TE-13, KYSE30, Eca109) and normal esophageal epithelial cells HET-1A. The cells with the lowest expression were selected, the negative control lentivirus (LV-NC) infection was used as the control group, and the recombinant lentivirus carrying SCAMP1-AS1 sequence (LV-SCAMP1-AS1) infection was used as the experimental group. RT-qPCR was used to detect the expression of SCAMP1-AS1 in esophageal cancer cells after infection. Cell counting kit 8 (CCK-8) and Transwell chamber method were used to detect the proliferation and migration ability of esophageal cancer cells. Bioinformatics methods predicted the target genes of SCAMP1-AS1, and dual luciferase reporter experiments verified the interaction of SCAMP1-AS1 with target gene. RT-qPCR detected the expression of target genes. Western blotting detected the expression of cell proliferation and migration phenotype proteins.Results:The relative expression level of SCAMP1-AS1 in esophageal cancer tissue was significantly lower than that in adjacent tissues (1.26 ± 0.48 vs. 8.03 ± 1.17, P<0.01). The relative expression levels of SCAMP1-AS1 in esophageal cancer cells EC9706, TE-13, KYSE30, Eca109 were all lower than that in normal esophageal epithelial cells (0.54 ± 0.05, 0.14 ± 0.02, 0.46 ± 0.07, 0.77 ± 0.05 vs.1.00 ± 0.06, P<0.05), and the expression of SCAMP1-AS1 in TE-13 cells was the lowest ( P<0.01). Compared with the control group, the expression of SCAMP1-AS1 in TE-13 cells in the experimental group was up-regulated ( P<0.01), the proliferation ability of the cells was reduced ( P<0.01), and the migration ability of the cells was reduced ( P<0.01). miR-483-5p was the direct target of SCAMP1-AS1. Compared with the control group, the expression of miR-483-5p was down-regulated in TE-13 cells in the experimental group ( P<0.01), and the expression of cell proliferation and migration phenotype proteins was down-regulated. Conclusions:The expression of lncRNA SCAMP1-AS1 is down-regulated in esophageal cancer. SCAMP1-AS1 can inhibit the proliferation and migration of esophageal cancer TE-13 cells by targeting the expression of miR-483-5p. SCAMP1-AS1 is expected to become a potential molecular therapeutic target for esophageal cancer.